Treatment of a secondary myelodysplastic syndrome after allogenic bone marrow transplantation using Mylotarg.
Hermida
Gerardo
G
Servicio de Hematología, Hospital General Yagüe, Burgos, Spain. ghermidaf@aehh.org
Manjón
Raquel
R
Rodríguez-Salazar
Isabel
I
Richard
Carlos
C
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000970:Antineoplastic Agents / Q000008:administration & dosage; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000209:etiology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology / Q000628:therapy; D012074:Remission Induction; D063268:Sialic Acid Binding Ig-like Lectin 3; D014184:Transplantation, Homologous / Q000009:adverse effects
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000970:Antineoplastic Agents; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3